Asymptomatic primary hyperparathyroidism: A medical perspective

Surgical Clinics of North America

Volumn 84, Issue 3, 2004, Pages 787-801

  Silverberg, Shonni J ^a   Bilezikian, John P ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL;

ANEMIA; BONE DENSITY; CLINICAL FEATURE; DISEASE COURSE; DNA DETERMINATION; FRACTURE; HEART DEATH; HUMAN; HYPERCALCIURIA; HYPERTENSION; KERATOPATHY; KIDNEY CALCIFICATION; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; MUSCLE ATROPHY; NEPHROLITHIASIS; PANCREATITIS; PARATHYROID CARCINOMA; PATHOPHYSIOLOGY; PEPTIC ULCER; PHENOTYPE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SKELETON; SYMPTOM; VITAMIN D DEFICIENCY;

BONE DISEASES; CARDIOVASCULAR DISEASES; GASTROINTESTINAL DISEASES; HUMANS; HYPERPARATHYROIDISM; KIDNEY DISEASES;

EID: 2442441191     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2004.03.002     Document Type: Review

References (74)

1. Albright F. A page out of history of hyperparathyroidism. J Clin Endocrinol Metab. 8:1948;637-657
2. Silverberg S.J., Bilezikian J.P. Hyperparathyroidism. Becker K.L. Principles and practice of endocrinology and metabolism. 3rd edition:2001;564-573 JB Lippincott, Philadelphia
3. Heath H. III, Hodgson S.F., Kennedy M.A. Primary hyperparathyroidism: incidence, morbidity, and potential economic impact in a community. N Engl J Med. 302:1980;189
4. Shane E. Parathyroid carcinoma. Bilezikian J.P., Marcus R., Levine M.A. The parathyroids. 2nd edition:2001;515-526 Academic Press, New York
5. Arnold A., Shattuck T.M., Mallya S.M., Krebs L.J., Costa J., Gallagher J., et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res. 17:2002;N30-N36
6. Farnebo F., Teh B.T., Kytola S., Svensson A., Phelan C., Sandelin K., et al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab. 83:1998;2627-2630
7. Cetani F., Pinchera A., Pardi E., Cianferotti L., Vignali E., Picone A., et al. No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas. J Bone Miner Res. 14:1999;878-882
8. Pausova Z., Soliman E., Amizuka N., Janicic N., Konrad E.M., Arnold A., et al. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 81:1996;2711-2718
9. Hakim J.P., Levine M.A. Absence of p53 point mutations in parathyroid adenomas and carcinoma. J Clin Endocrinol Metab. 478:1994;103-106
10. El-Hajj Fuleihan G., Brown E.M., Heath H. III. Familial benign hypocalciuric hypercalcemia and neonatal primary hyperparathyroidism. Bilezikian J.P., Raisz L.G., Rodan G.A. Principles of bone biology. 2nd editiion:2001;1031-1045 Academic Press, San Diego (CA)
11. Silverberg S.J., Bilezikian J.P. Clinical presentation of primary hyperparthyroidism in the United States. Bilezikian J.P., Marcus R., Levine M.A. The parathyroids. 2nd edition:2001;349-360 Academic Press, New York
12. Fitzpatrick L.A. Acute primary hyperparathyroidism. Bilezikian J.P., Marcus R., Levine M.A. The parathyroids. 2nd edition:2001;527-553 Academic Press, New York
13. Harinarayan D.V., Gupta N., Kochupillai N. Vitamin D status in primary hyperparathyroidism in India. Clin Endocrinol (Oxf). 43:1995;351-358
14. Mithal A., Bandeira F., Meng X., Silverberg S.J., Shi Y., Mishra S.K., et al. Clinical presentation of primary hyperparthyroidism: India, Brazil and China. Bilezikian J.P., Marcus R., Levine M.A. The parathyroids. 2nd edition:2001;375-386 Academic Press, New York
15. Bilezikian J.P., Meng X., Shi Y., Silverberg S.J. Primary hyperparathyroidism in women: New York and Beijing (a tale of two cities). Int J Fertility Women's Health. 45:2000;158-165
16. Woodhouse N.J.Y., Doyle F.H., Joplin G.F. Vitamin D deficiency and primary hyperparathyroidism. Lancet. 7:1971;283-287
17. Lumb G.A., Stanbury S.W. Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med. 56:1974;833-839
18. Silverberg S.J., Shane E., Dempster D.W., Bilezikian J.P. Vitamin D insufficiency in primary hyperparathyroidism. Am J Med. 107:1999;561-567
19. Silverberg S.J., Bilezikian J.P. "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab. 88:2003;5348-5352
20. Rao D.S., Wilson R.J., Kleerekoper M., Parfitt A.M. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 67:1988;1294-1298
21. Silverberg S.J., Shane E., de la Cruz L., Dempster D.W., Feldman F., Seldin D., et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 4:1989;283-291
22. Silverberg S.J., Locker F.G., Bilezikian J.P. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab. 81:1996;4007-4012
23. Gao P., Scheibel S., D'Amour P., John M.R., Rao S.D., Schmidt-Gayk H., et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 16:(4):2001;605-614
24. Silverberg S.J., Brown I., LoGerfo P., Gao P., Cantor T., Bilezikian J.P. Clinical utility of an immunoradiometric assay for whole PTH (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab. 88:2003;4725-4730
25. Parisien M., Cosman F., Mellish R.W.E., Schnitzer M., Nieves J., Silverberg S.J., et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic and normal women. J Bone Miner Res. 10:1995;1393-1399
26. Dempster D.W., Parisien M., Silverberg S.J., Liang X.-G., Schnitzer M., Shen V., et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab. 84:1999;1562-1566
27. Parisien M., Dempster D.W., Shane E., Bilezikian J.P. Histomorphometric analysis of bone in primary hyperparathyroidism. Bilezikian J.P., Marcus R., Levine M.A. The parathyroids. 2nd edition:2001;423-436 Academic Press, New York
28. Wilson R.J., Rao D.S., Ellis B., Kleevekoper M., Parfitt A.M. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med. 109:1988;959-962
29. Larsson K., Llunghall S., Krusemo U.B., Naessen T., Lindh E., Persson I. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Int Med. 234:1993;585-593
30. Melton L.J., Atkinson E.J., O'Fallon W.M., Heath H. III. Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med. 152:1992;2269-2273
31. Khosla S., Melton L.J., Wermers R.A., Crowson C.D., O'Fallon W.M., Riggs B.L. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 14:1999;1700-1707
32. Silverberg S.J., Shane E., Jacobs T.P., Siris E.S., Gartenberg F., Seldin D., et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism, 1985-1990. Am J Med. 89:1990;327-334
33. Palmer M., Adami H.O., Bergstrom R., Akerstrom G. Mortality after surgery for PHPT. Surgery. 102:1987;1-7
34. Hedback G., Tisell L.E., Bengtsson B.A., Hedman I., Oden A. Premature death in patients operated on for PHPT. World J Surg. 14:1990;829-835
35. Ljunghall S., Jakobsson S., Joborn C., Palmer M., Rastad J., Akerstrom G. Longitudinal studies of mild PHPT. J Bone Miner Res. 6:1991;S11-S16
36. Hedback G., Oden A. Increaed risk of death from PHPT - an update. Eur J Clin Invest. 28:1998;271-276
37. Wermers R., Khosla S., Atkinson E.J., Grant C.S., Hodgson S.F., O'Fallon W.M., et al. Survival after diagnosis of PHPT: a population based study. Am J Med. 104:1998;115-122
38. Nainby-Luxmoore J.C., Langford H.G., Nelson N.C., Watson R.L., Barnes T.Y. A case-comparison study of hypertension and hyperparathyroidism. J Clin Endocrinol Metab. 55:1982;303-306
39. Ringe J.D. Reversible hypertension in primary hyperparathyroidism-pre- and postoperative blood pressure in 75 cases. Klin Wochenschr. 62:1984;465-469
40. Gennari C., Nami R., Gonnelli S. Hypertension and primary hyperparathyroidism: role of the adrenergic and plasma renin angiotensin systems. Miner Electrolyte Metab. 21:1995;77-81
41. Niederle B., Stefenelli T., Glogar D., Woloszczuk W., Roka R., Mayr H. Cardiac calcific deposits in patients with primary hyperparathyroidism: preliminary results of a prospective echocardiographic study. Surgery. 108:1990;1052-1056. [discussion: 1056-7]
42. Dalberg K., Brodin L.A., Juhlin-Dannfelt A., Farnebo L.O. Cardiac function in primary hyperparathyroidism before and after operation: an echocardiographic study. Eur J Surg. 162:1996;171-176
43. Stefenelli T., Mayr H., Berger-Klein J., Globits S., Wolosczuk W., Niederle B. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med. 95:1993;197-202
44. Stefenelli T., Abela C., Frank H., Koller-Strametz J., Globits S., Berger-Klein J., et al. Cardiac abnormalities in patients with PHPT: imlications for follow-up. J Clin Endocrinol Metab. 82:1997;106-112
45. Piovesan A., Molineri N., Casasso F., Emmolo I., Ugliengo G., Cesarion F., et al. Left ventricular hypertrophy in PHPT. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf). 50:1999;321-328
46. Lakatos P., Tatrai A., Foldes J., Harvath C., Mako J., Stern P.H. Endothelin concentrations are elevated in plasma of patients with primary and secondary hyperparathyroidism. Calcif Tissue Int. 58:1996;70-71
47. Nilsson I.L., Aberg J., Rastad J., Lind L. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery. 126:1999;1049-1055
48. Neunteufl T., Katzenschlager R., Abela C., Kostner K., Niederle B., Weidinger F., et al. Impairment of endothelium-independent vasodilation in patients with hypercalcemia. Cardiovasc Res. 40:1998;396-401
49. Kosch M., Hausberg M., Vrombrock K., Kisters K., Heinz Rahn K., Barenbrock M. Studies on flow-mediated vasodilation and intima-media thickness of the brachial artery in patients with primary hyperparathyroidism. Am J Hypertens. 3:2000;759-764
50. Silverberg S.J. Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res. 217:(Suppl 2):2002;N117-N125
51. Patten B., Bilezikian J., Mallette L.E., Prince A., Engel W.K., Aurbach G.D. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med. 80:1971;182-193
52. Turken S.A., Cafferty M., Silverberg S.J. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med. 87:1989;553-557
53. Brown G.G., Preisman R.C., Kleerekoper M.D. Neurobehavioral symptoms in mild primary hyperparathyroidism: related to hypercalcemia but not improved by parathyroidectomy. Henry Ford Hosp Med J. 35:1987;211-215
54. Solomon B.L., Schaaf M., Smallridge R.C. Psychologic symptoms before and after parathyroid surgery. Am J Med. 96:1994;101-106
55. Clark O.H. Presidential address: "asymptomatic" primary hyperparathyroidism: is parathyroidectomy indicated? Surgery. 116:1994;947
56. Pasieka J.L., Parsons L. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg. 22:1998;513-519
57. Burney R.E., Jones K.R., Christy B., Thompson N.W. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery. 125:1999;608-614
58. Bilezikian J.P., Potts J.T., El-Hajj Fuleihan G., Kleerekoper M., Neer R., Peacock M., et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 87:2002;5353-5361
59. Rubin M.R., Silverberg S.J. Rheumatic manifestations of primary hyperparathyroidism and PTH therapy. Current Rheumatol Rep. 4:2002;179-185
60. Potts JT Jr, Fradkin JE, Aurbach GD, Bilezikian JP, Raisz LG, editors. Proceedings of the NIH consensus development conference on diagnosis and management of asymptomatic primary hyperparathyroidism. Bethesda, Maryland, October 29-31, 1990. J Bone Miner Res 1991;6(Suppl 2):S1-166.
61. Silverberg S.J., Shane E., Jacobs T.P., Siris E., Bilezikian J.P. The natural history of treated and untreated asymptomatic primary hyperparathyroidism: a ten year prospective study. N Engl J Med. 341:1999;1249-1255
62. Silverberg S.J., Locker F.G., Bilezikian J.P. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab. 81:1996;4007-4012
63. Silverberg S.J., Brown I., Bilezikian J.P. Youthfulness as a criterion for surgery in primary hyperparathyroidism. Am J Med. 113:2002;681-684
64. Locker F.G., Silverberg S.J., Bilezikian J.P. Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med. 102:1997;543-550
65. Marcus R. The role of estrogens and related compounds in the management of primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N146-N149
66. Grey A.B., Stapleton J.P., Evans M.C., Tatnell M.A., Reid I.R. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. Ann Intern Med. 125:1996;360-368
67. Rubin M.A., Lee K.H., McMahon D.J., Silverberg S.J. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 88:2003;1174-1178
68. Parker C.R., Blackwell P.J., Fairbairn K.J., Hosking D.J. Alendronate in the treatment of primary hyperparathyroidism-related osteoporosis: a 2-year study. J Clin Endocrinol Metab. 87:2002;4482-4489
69. Chow C.C., Chan W.B., Li J.K.Y., Chan N.N., Chan M.H.M., Ko G.T.C., et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 88:2003;581-587
70. Hassani S., Braunstein G.D., Seibel M.J., Brickman A.S., Geola F.L., Pekary A.E., et al. Alendronate therapy of primary hyperparathyroidism. Endocrinologist. 11:2001;459-464
71. Rossini M., Gatti D., Isaia G., Sartori L., Braga V., Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 16:2001;113-119
72. Khan A.A., Bilezikian J.P., Kung A.W.C., Ahmed M.M., Dubois S.J., Ho A.Y.Y., et al. Alendronate in primary hyperapathyroidism. J Clin Endocrinol Metab. 2004;. in press
73. Shoback D.M., Bilezikian J.P., Turner S.A., McCary L.C., Guo M.D., Peacock M. The calcimimetic AMG 073 normalizes serum calcium in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 88:2003;5644-5649
74. Peacock M., Scumpia S., Bolognese M.A., et al. Long term control of primary hyperparathyroidism with cinacalcet HCl. J Bone Miner Res. 18:2003;S16